Komori
Solasia Pharma K.K. (4597) · InitiativeDroppedLatest Financial results presentation materials (2026-08-13): "Advanced"

Joint commercialization study for functional fluorescent probes with Goryo Chemical

First written in FY2023. 2 of 4 entries say "Advanced", first in 2026-05-15. Latest entry: 2026-08-13.

4entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023 – FY20252024: 120242025: 020252026: 32026
Same theme, other companies
Consideration of Joint Commercialization of GCP-006 with 五稜化薬A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2025DroppedAnnual report
    五稜化薬株式会社との機能性蛍光プローブ及びGCP-006に関する共同事業化検討について、当年度の主要な開発活動及びリスクの記載では個別の言及がなくなった。
  3. FY2023First statedAnnual report

    「In 2023, the Company entered into a joint commercialization study agreement with Goryo Chemical, under which the parties would jointly conduct business-development and clinical-development activities relating to pharmaceutical businesses such as navigation drugs for cancer surgery using functional fluorescent probes based on Goryo Chemical’s technology. As the first target, the parties began studying the development and commercialization of GCP-006, a navigation drug for breast cancer.」

    The Company entered into a joint commercialization study agreement with Goryo Chemical and began studying the development and commercialization of GCP-006, a navigation drug for breast cancer using functional fluorescent probes.
Moved together

"SP-01: Sancuso® Approved and Launched in China" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22222★12345
  1. ★This thread
  2. 1SP-01: Sancuso® Approved and Launched in China2×
  3. 2Combined Use of the China Direct-Sales Model and Derived Models for Other Regions2×
  4. 3Development and Commercialization of SP-04 PledOx in Japan and Asia2×
  5. 4Expanding SP-04 PledOx’s Indications to Paclitaxel and Other Treatments2×
  6. 5Investment in HikariQ Health and Its Conversion into an Equity-Method Affiliate2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet. It last moved in the Financial results presentation materials of 2026-08-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Joint commercialization study for functional fluorescent probes with Goryo Chemical | Solasia Pharma K.K. (4597) | Komori